

» PŘEHLEDOVÉ ČLÁNKY

ANTIDEPRESIVA V LÉČBĚ DEPRESIVNÍ PORUCHY V TĚHOTENSTVÍ: LÉČIT, NEBO NELÉČIT?

63. Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. *JAMA Psychiatry*. 2020;77(12):1246-1255.
64. Bérard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. *Am J Obstet Gynecol*. 2015;212(6):799.e1-799.e13.
65. Uguz F. Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses. *Expert Opin Drug Saf*. 2020;19(12):1595-1604.
66. Einarson A, Pistelli A, De Santis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine. *J Obstet Gynaecol Can*. 2008;30(8):696-701.
67. O'Brien L, Einarson TR, Sarkar M, et al. Does paroxetine cause cardiac malformations? *J Obstet Gynaecol Can*. 2008;30(8):696-701.
68. Petersen I, Evans SJ, Gilbert R, et al. Selective serotonin reuptake inhibitors and congenital heart anomalies: comparative cohort studies of women treated before and during pregnancy and their children. *J Clin Psychiatry*. 2016;77(1):e36-e42.
69. Ban L, Gibson JE, West J, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. *BJOG*. 2014;121(12):1471-1481.
70. Hutchison SM, Brain U, Grunau RE, et al. Associations between maternal depressive symptoms and selective serotonin reuptake inhibitor antidepressant treatment on internalising and anxiety behaviours in children: 12-year longitudinal study. *BJPsych Open*. 2023;9(2):e26.
71. Rommel AS, Bergink V, Liu X, et al. Long-term effects of intrauterine exposure to antidepressants on physical, neurodevelopmental, and psychiatric outcomes: a systematic review. *J Clin Psychiatry*. 2020;81(3):20r13461.
72. Campbell KSJ, Brain U, Hanley GE, et al. Maternal depressed mood and serotonergic antidepressant treatment during pregnancy differentially shape the continuity between fetal-newborn neurobehaviour. *Early Hum Dev*. 2024;198:106-129.
73. Mezzacappa A, Lasica PA, Gianfagna F, et al. Risk for autism spectrum disorders according to period of prenatal antidepressant exposure: a systematic review and meta-analysis. *JAMA Pediatr*. 2017;171(6):555-563.
74. Sujan AC, Rickert ME, Öberg AS, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. *JAMA*. 2017;317(15):1553-1562.
75. Clements CC, Castro VM, Blumenthal SR, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. *Mol Psychiatry*. 2015;20(6):727-734.
76. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. *Gen Hosp Psychiatry*. 2009;31(5):403-413.
77. Česká psychiatrická společnost ČLS JEP. Doporučené postupy psychiatrické péče 2024 – Specifika léčby depresivní epizody v těhotenství. Praha; 2024.
78. Haskey C, Galbally M. Mood stabilizers in pregnancy and child developmental outcomes: a systematic review. *Aust N Z J Psychiatry*. 2017;51(11):1087-1097.



FACEBOOK

<https://www.facebook.com/SolenMedicalEducation/>

@SolenMedicalEducation



INSTAGRAM

https://www.instagram.com/solen_cz/

@solen_cz



LINKEDIN

<https://www.linkedin.com/company/solen-medical-education/>

#solenmedicaleducation

» ODEMČENÉ **AKTUÁLNÍ ČLÁNKY**

» **PŘEHLED** O VZDĚLÁVACÍCH AKCÍCH

» UPOZORNĚNÍ NA **ZVÝHODNĚNÉ CENY**

» **SOUTĚŽE** O VSTUPENKY NA KONGRESY

» INFORMACE O **ON-LINE** KURZECH

» NOVINKY V **E-SHOPU**

... a mnoho dalšího

... **nenechte si ujít aktuální informace**
o možnostech medicínského vzdělávání